Audalia Completes $450K Placement to Advance Medcalf Permits and Design

Placement Supports Critical Medcalf Project Milestones

Audalia Resources (ASX:ACP) has completed a $450,000 placement by issuing 15 million shares at 3 cents apiece to a sophisticated investor. The capital injection is designed to fund the next steps in advancing the Medcalf vanadium-titanium-iron project, specifically targeting mining design, permit acquisition, and secondary approvals. This fresh capital will also bolster the company’s general working capital position.

This placement follows an earlier announcement outlining the company’s intent to raise funds to sustain progress amid a tightening cash balance. The $450,000 raise aligns with Audalia’s strategy to maintain momentum after the release of its maiden Ore Reserve and updated Pre-feasibility Study, which presented two development pathways with strong economic returns but underscored the need for further funding to unlock project potential. The company’s recent capital raise plans confirm this ongoing focus on securing sufficient financial resources.

Regulatory Compliance and Share Issuance Details

The shares were issued without disclosure under Part 6D.2 of the Corporations Act 2001, with the company lodging a Secondary Trading Notice under section 708A(5)(e) to ensure the shares can be traded without restriction. Audalia confirmed compliance with the Act’s continuous disclosure provisions and stated that no material information has been withheld that would affect investors’ assessment of the company’s prospects or the rights attached to the new shares.

As Audalia continues to navigate the regulatory landscape, the funds raised will be critical in progressing the mining permit and securing the necessary secondary approvals that remain outstanding. These regulatory milestones are prerequisites for advancing towards construction and eventual production at Medcalf, a project with a reported maiden Ore Reserve of 11.77 million tonnes at 11.0% TiO2 and a projected mine life of around nine years. The company’s ongoing efforts to secure funding and permits are vital in translating these reserves into operational reality, as highlighted in its recent maiden Ore Reserve announcement.

Funding Strategy Remains Active Amid Development Challenges

While this placement provides a necessary capital boost, Audalia is actively assessing all funding alternatives to ensure it can meet the financial demands of the remaining regulatory approvals and permit processes. The company has previously indicated that total funding requirements to bring Medcalf into production could range significantly, reflecting the complexity and scale of the project. This $450,000 placement represents a tactical step in a broader capital strategy that will likely require further injections to fully realise development plans.

Investors should watch how Audalia balances its funding needs with project milestones and market conditions, as the timing and success of permit approvals will be key determinants of the company’s trajectory. The Medcalf Project’s strong economic indicators from the Pre-feasibility Study provide a promising backdrop, but execution risks remain as the company moves from resource definition to development.